Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.68
AGN's Cash to Debt is ranked higher than
65% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. AGN: 1.68 )
AGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 1.9
Current: 1.68

0.27
1.9
Equity to Asset 0.62
AGN's Equity to Asset is ranked higher than
69% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. AGN: 0.62 )
AGN' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.65
Current: 0.62

0.38
0.65
Interest Coverage 24.12
AGN's Interest Coverage is ranked higher than
60% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. AGN: 24.12 )
AGN' s 10-Year Interest Coverage Range
Min: 3.29   Max: 46.04
Current: 24.12

3.29
46.04
F-Score: 8
Z-Score: 9.68
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating margin (%) 28.72
AGN's Operating margin (%) is ranked higher than
96% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. AGN: 28.72 )
AGN' s 10-Year Operating margin (%) Range
Min: -1.34   Max: 28.72
Current: 28.72

-1.34
28.72
Net-margin (%) 15.64
AGN's Net-margin (%) is ranked higher than
88% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. AGN: 15.64 )
AGN' s 10-Year Net-margin (%) Range
Min: -6.96   Max: 20.39
Current: 15.64

-6.96
20.39
ROE (%) 15.24
AGN's ROE (%) is ranked higher than
91% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AGN: 15.24 )
AGN' s 10-Year ROE (%) Range
Min: -12.96   Max: 33.78
Current: 15.24

-12.96
33.78
ROA (%) 9.32
AGN's ROA (%) is ranked higher than
90% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. AGN: 9.32 )
AGN' s 10-Year ROA (%) Range
Min: -6.76   Max: 16.71
Current: 9.32

-6.76
16.71
ROC (Joel Greenblatt) (%) 128.77
AGN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. AGN: 128.77 )
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4.9   Max: 128.77
Current: 128.77

-4.9
128.77
Revenue Growth (%) 9.30
AGN's Revenue Growth (%) is ranked higher than
75% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AGN: 9.30 )
AGN' s 10-Year Revenue Growth (%) Range
Min: -3.3   Max: 19.7
Current: 9.3

-3.3
19.7
EBITDA Growth (%) 60.90
AGN's EBITDA Growth (%) is ranked higher than
97% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. AGN: 60.90 )
AGN' s 10-Year EBITDA Growth (%) Range
Min: -46   Max: 96
Current: 60.9

-46
96
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

AGN Guru Trades in Q2 2013

Paul Tudor Jones 14,400 sh (New)
Ray Dalio 249,341 sh (+2759.74%)
Joel Greenblatt 29,690 sh (+722.89%)
Steven Cohen 66,132 sh (+193.13%)
Jeremy Grantham 860,731 sh (+106.05%)
Jim Simons 1,000,660 sh (+59.93%)
Pioneer Investments 1,220,561 sh (+21.08%)
Dodge & Cox 3,564 sh (unchged)
Mario Gabelli 126,914 sh (-7.85%)
Ken Fisher 9,015 sh (-18.77%)
Frank Sands 9,598,964 sh (-24.86%)
» More
Q3 2013

AGN Guru Trades in Q3 2013

George Soros 75,000 sh (New)
Steven Cohen 615,599 sh (+830.86%)
Joel Greenblatt 63,459 sh (+113.74%)
Jeremy Grantham 903,161 sh (+4.93%)
Mario Gabelli 127,569 sh (+0.52%)
Daniel Loeb 17,500 sh (unchged)
Dodge & Cox 3,564 sh (unchged)
Ray Dalio 226,041 sh (-9.34%)
Ken Fisher 7,237 sh (-19.72%)
Frank Sands 7,422,715 sh (-22.67%)
Paul Tudor Jones 10,700 sh (-25.69%)
Pioneer Investments 855,672 sh (-29.9%)
Jim Simons 386,360 sh (-61.39%)
» More
Q4 2013

AGN Guru Trades in Q4 2013

Andreas Halvorsen 1,438,989 sh (New)
George Soros 90,000 sh (+20%)
Mario Gabelli 127,769 sh (+0.16%)
Dodge & Cox 3,564 sh (unchged)
Jim Simons Sold Out
Frank Sands Sold Out
Pioneer Investments 819,803 sh (-4.19%)
Ken Fisher 6,882 sh (-4.91%)
Jeremy Grantham 727,994 sh (-19.39%)
Joel Greenblatt 34,897 sh (-45.01%)
Paul Tudor Jones 3,600 sh (-66.36%)
Steven Cohen 139,119 sh (-77.4%)
Ray Dalio 40,719 sh (-81.99%)
» More
Q1 2014

AGN Guru Trades in Q1 2014

Bill Ackman 597,431 sh (New)
Jim Simons 164,456 sh (New)
Paul Tudor Jones 9,987 sh (+177.42%)
Jeremy Grantham 1,101,751 sh (+51.34%)
Pioneer Investments 863,660 sh (+5.35%)
Dodge & Cox 3,564 sh (unchged)
George Soros Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 126,924 sh (-0.66%)
Ken Fisher 6,685 sh (-2.86%)
Joel Greenblatt 18,843 sh (-46%)
Ray Dalio 18,499 sh (-54.57%)
Steven Cohen 20,480 sh (-85.28%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 Sold Out 0.09%$110.28 - $131.43 $ 172.4342%0
Joel Greenblatt 2014-03-31 Reduce -46%0.04%$110.28 - $131.43 $ 172.4342%18843
Ray Dalio 2014-03-31 Reduce -54.57%0.02%$110.28 - $131.43 $ 172.4342%18499
Frank Sands 2013-12-31 Sold Out 1.9%$88.48 - $110.85 $ 172.4381%0
Ray Dalio 2013-12-31 Reduce -81.99%0.14%$88.48 - $110.85 $ 172.4381%40719
Joel Greenblatt 2013-12-31 Reduce -45.01%0.09%$88.48 - $110.85 $ 172.4381%34897
Frank Sands 2013-09-30 Reduce -22.67%0.61%$84.24 - $92.63 $ 172.4392%7422715
Joel Greenblatt 2013-09-30 Add 113.74%0.1%$84.24 - $92.63 $ 172.4392%63459
George Soros 2013-09-30 New Buy0.07%$84.24 - $92.63 $ 172.4392%75000
Frank Sands 2013-06-30 Reduce -24.86%1.27%$81.99 - $116.17 $ 172.4366%9598964
Ray Dalio 2013-06-30 Add 2759.74%0.17%$81.99 - $116.17 $ 172.4366%249341
Joel Greenblatt 2013-06-30 Add 722.89%0.1%$81.99 - $116.17 $ 172.4366%29690
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Allergan Inc

Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...
Stocks with High Forward Rate of Return, Donald Yacktman’s Measure
Among the criteria Donald Yacktman, conservative value investor who runs the risk-averse Yacktman Asset Management, uses to judge the attractiveness of a stock, he strongly prizes a high “forward rate of return.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 42.40
AGN's P/E(ttm) is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.50 vs. AGN: 42.40 )
AGN' s 10-Year P/E(ttm) Range
Min: 16.7   Max: 100.02
Current: 42.4

16.7
100.02
P/B 7.70
AGN's P/B is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. AGN: 7.70 )
AGN' s 10-Year P/B Range
Min: 2.4   Max: 15.92
Current: 7.7

2.4
15.92
P/S 8.00
AGN's P/S is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. AGN: 8.00 )
AGN' s 10-Year P/S Range
Min: 2.18   Max: 8.05
Current: 8

2.18
8.05
PFCF 33.70
AGN's PFCF is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 33.70 )
AGN' s 10-Year PFCF Range
Min: 16.97   Max: 143.81
Current: 33.7

16.97
143.81
EV-to-EBIT 27.24
AGN's EV-to-EBIT is ranked higher than
78% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. AGN: 27.24 )
AGN' s 10-Year EV-to-EBIT Range
Min: 12.3   Max: 773.4
Current: 27.24

12.3
773.4
PEG 1.50
AGN's PEG is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 356.67 vs. AGN: 1.50 )
AGN' s 10-Year PEG Range
Min: 0.41   Max: 12.32
Current: 1.5

0.41
12.32
Shiller P/E 70.00
AGN's Shiller P/E is ranked higher than
78% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 70.00 )
AGN' s 10-Year Shiller P/E Range
Min: 32.89   Max: 118.3
Current: 70

32.89
118.3
Current Ratio 4.37
AGN's Current Ratio is ranked higher than
85% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AGN: 4.37 )
AGN' s 10-Year Current Ratio Range
Min: 0.89   Max: 4.5
Current: 4.37

0.89
4.5
Quick Ratio 4.14
AGN's Quick Ratio is ranked higher than
87% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. AGN: 4.14 )
AGN' s 10-Year Quick Ratio Range
Min: 0.78   Max: 4.26
Current: 4.14

0.78
4.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.10
AGN's Dividend Yield is ranked lower than
94% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. AGN: 0.10 )
AGN' s 10-Year Dividend Yield Range
Min: 0.11   Max: 0.63
Current: 0.1

0.11
0.63
Dividend Payout 0.08
AGN's Dividend Payout is ranked higher than
100% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 0.08 )
AGN' s 10-Year Dividend Payout Range
Min: 0.04   Max: 6
Current: 0.08

0.04
6
Yield on cost (5-Year) 0.10
AGN's Yield on cost (5-Year) is ranked lower than
93% of the 459 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. AGN: 0.10 )
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.11   Max: 0.63
Current: 0.1

0.11
0.63
Share Buyback Rate 0.70
AGN's Share Buyback Rate is ranked higher than
86% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.50 vs. AGN: 0.70 )
AGN' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -4.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 126.80
AGN's Price/Net Current Asset Value is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 126.80 )
AGN' s 10-Year Price/Net Current Asset Value Range
Min: 58.67   Max: 438.7
Current: 126.8

58.67
438.7
Price/Tangible Book 19.40
AGN's Price/Tangible Book is ranked higher than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. AGN: 19.40 )
AGN' s 10-Year Price/Tangible Book Range
Min: 3.38   Max: 277.05
Current: 19.4

3.38
277.05
Price/DCF (Projected) 3.30
AGN's Price/DCF (Projected) is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 3.30 )
AGN' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 6.46
Current: 3.3

1.3
6.46
Price/Median PS Value 1.60
AGN's Price/Median PS Value is ranked higher than
63% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. AGN: 1.60 )
AGN' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 2.3
Current: 1.6

0.27
2.3
Price/Peter Lynch Fair Value 1.70
AGN's Price/Peter Lynch Fair Value is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 1.70 )
AGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.89   Max: 5.65
Current: 1.7

0.89
5.65
Price/Graham Number 5.90
AGN's Price/Graham Number is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AGN: 5.90 )
AGN' s 10-Year Price/Graham Number Range
Min: 1.58   Max: 60.77
Current: 5.9

1.58
60.77
Earnings Yield (Greenblatt) 3.70
AGN's Earnings Yield (Greenblatt) is ranked higher than
67% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. AGN: 3.70 )
AGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.1
Current: 3.7

0.1
8.1
Forward Rate of Return (Yacktman) 25.75
AGN's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. AGN: 25.75 )
AGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.6   Max: 51
Current: 25.75

-24.6
51

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:AG4.Germany
Allergan, Inc., was founded in 1950 and incorporated in Delaware in 1977. The Company is a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential. The Company discovers, develops and commercializes specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries around the world. It is engaged in specialty pharmaceutical, biologic and medical device research and development, with global efforts targeting products and technologies related to eye care, skin care, neuromodulators, medical aesthetics, obesity intervention, urology and neurology. The Company operates its business on the basis of two reportable segments - specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a range of pharmaceutical products, including: ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, allergy and retinal diseases; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, other prescription and over-the-counter skin care products and urologics products. The medical devices segment produces a range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products; and facial aesthetics products. The Company provides global marketing strategy teams to ensure development and execution of a consistent marketing strategy for its products in all geographic regions that share similar distribution channels and customers. The Company faces intense competition from generic drug manufacturers in the United States and internationally. The Company is subject to federal, state, local and foreign environmental laws and regulations.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
George Soros Reveals His Largest Stake Jul 23 2014 
Bill Ackman Sits Down With Bloomberg - Allergan Is Not Being Raided In Valeant Deal Apr 25 2014 
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen Apr 23 2014 
Bill Ackman Presentation - Perspective from Allergan's Largest Shareholder Apr 23 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Weekly CEO Sells Highlight: Cardinal Health, Envision Healthcare Holdings, Tableau Software and Alle Feb 16 2014 
Stock with High Forward Rate of Return, Donald Yacktman’s Measure Dec 26 2013 
Insiders Are Buying Ophthotech Oct 08 2013 
Sands Capital Management Update, Sells AAPL, Cuts GOOG and Others Sep 01 2013 

More From Our Partners
Puma Biotech Surges on Positive Results on Neratinib - Analyst Blog Jul 23 2014 - ZACKS

More From Other Websites
Republican lawmaker to grill U.S. SEC over Ackman tactics Jul 23 2014
Correction: Blog points out Valeant's diverse portfolio is key to its success Jul 23 2014
Ominous Signs For Valeant In The Allergan Q2 Earnings Call Jul 23 2014
ALLERGAN INC Files SEC form 8-K, Other Events Jul 23 2014
[$$] Allergan Leaves Investors Smiling Jul 23 2014
Allergan employees have mixed emotions as layoffs loom Jul 22 2014
BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share Jul 22 2014
Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts Jul 22 2014
Allergan: Waiting for a Deal Jul 22 2014
[$$] Allergan to Cut 13% of Workforce Jul 22 2014
Allergan upgraded by UBS Jul 22 2014
[video] Upgrades for Allergan and Chipotle, Amazon Downgraded Jul 22 2014
Allergan Reiterates Plan to Preempt Valeant Offer Jul 22 2014
UPDATE: UBS Securities Upgrades Allergan On Conference Call Takeaways Jul 22 2014
Company News for July 22, 2014 Jul 22 2014
Will This Analyst Upgrade Help Allergan (AGN) Stock Today? Jul 22 2014
Allergan price target raised to $230 from $202 at BMO Capital Jul 22 2014
Allergan stand alone value now above Valeant offer, says Bernstein Jul 22 2014
Allergan to slash workforce by 1,500 Jul 22 2014
Allergan EPS Growth, Job Cuts Counter Valeant Jul 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide